Polyarteritis Nodosa (cont.)
William C. Shiel Jr., MD, FACP, FACR
Dr. Shiel received a Bachelor of Science degree with honors from the University of Notre Dame. There he was involved in research in radiation biology and received the Huisking Scholarship. After graduating from St. Louis University School of Medicine, he completed his Internal Medicine residency and Rheumatology fellowship at the University of California, Irvine. He is board-certified in Internal Medicine and Rheumatology.
Catherine Burt Driver, MD
Catherine Burt Driver, MD, is board certified in internal medicine and rheumatology by the American Board of Internal Medicine. Dr. Driver is a member of the American College of Rheumatology. She currently is in active practice in the field of rheumatology in Mission Viejo, Calif., where she is a partner in Mission Internal Medical Group.
In this Article
- Polyarteritis nodosa (PAN) facts
- What is polyarteritis nodosa (PAN)?
- What are causes and risk factors for polyarteritis nodosa?
- What are symptoms and signs of polyarteritis nodosa?
- How is polyarteritis nodosa diagnosed?
- What is the treatment for polyarteritis nodosa?
- What is the outlook (prognosis) of polyarteritis nodosa?
- Can polyarteritis nodosa be prevented?
- Find a local Rheumatologist in your town
What is the treatment for polyarteritis nodosa?
Polyarteritis is a serious illness that can be fatal. Treatment is directed toward decreasing the inflammation of the arteries by suppressing the immune system. Medications used to treat polyarteritis nodosa include high-dose intravenous and oral cortisone medications such as prednisone, as well as immunosuppressive drugs such as cyclophosphamide (Cytoxan) or azathioprine (Imuran).
When hepatitis B is present in patients with polyarteritis, antiviral medications (such as vidarabine and interferon-alpha) are used as primary treatments. Treatments have included various combinations of antiviral medications, plasma exchange, and immunosuppressive drugs.
What is the outlook (prognosis) of polyarteritis nodosa?
The outlook for patients with polyarteritis nodosa depends on the degree of damage to affected organs and the response to treatments. For those patients with underlying hepatitis B infection, eradication of the virus is essential for optimal outcome.
Can polyarteritis nodosa be prevented?
The only prevention for polyarteritis nodosa is to avoid the risk of hepatitis B.
Medically reviewed by Kirkwood Johnston, MD; American Board of Internal Medicine with subspecialty in Rheumatology
Koopman, William, et al., eds. Clinical Primer of Rheumatology. Philadelphia: Lippincott Williams & Wilkins, 2003.
Ruddy, Shaun, et al., eds. Kelley's Textbook of Rheumatology. Philadelphia: W.B. Saunders Co., 2000.
Get the latest treatment options